This is an application to develop an entirely new approach to the treatment of chronic HBV infection. Briefly, a combination strategy using the antigen reduction properties of glucosidase inhibitors with an antigen-derived vaccine will be used. Circulating levels of particles containing the viral envelope glycoproteins SHBs (S), MHBs (M) and LHBs (L) characterize chronic HBV infection. The hypothesis that selective reductions in MHBs (and LHBs) antigenemia are sufficient to enhance and complement therapeutic vaccination will be determined. Recent work suggests that animals and people chronically infected with hepadnaviruses possess the potential to mount putative beneficial immunological responses to the virus. It appears that this response can be enhanced or enabled by vaccination using hepadna viral glycoproteins, following reduction of antigenemia with highly effective antiviral agents as demonstrated in the woodchuck model of hepadnavirus infection. We have shown that imino sugar glucosidase inhibitors are effective in selectively reducing the amount of HBV envelope proteins secreted from chronically infected cells in tissue culture as well as, in a much more limited study, woodchucks. Thus glucosidase inhibitors could be ideal complements to vaccine-based therapies by selectively reducing antigen burden. Therefore, the ability of glucosidase inhibitors to selectively reduce HBV envelope antigen levels and enhance the efficacy of antigen based hepatitis vaccines, woodchucks chronically infected with hepadnavirus, will be determined. Tissue culture studies to identify an optimal and appropriate glucosidase inhibitor, and woodchuck studies to determine the feasibility of this approach are proposed. The possibility of an antiviral therapy for eAntigen negative HBV carriers makes this approach all the more compelling.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI053884-01
Application #
6577640
Study Section
Special Emphasis Panel (ZAI1-ALR-M (S1))
Program Officer
Johnson, Leslye D
Project Start
2002-09-30
Project End
2007-06-30
Budget Start
2002-09-30
Budget End
2003-06-30
Support Year
1
Fiscal Year
2002
Total Cost
$437,672
Indirect Cost
Name
Thomas Jefferson University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Norton, Pamela A; Menne, Stephan; Sinnathamby, Gomathinayagam et al. (2010) Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks. Hepatology 52:1242-50
Simsek, Ender; Sinnathamby, Gomathinayagam; Block, Timothy M et al. (2009) Inhibition of cellular alpha-glucosidases results in increased presentation of hepatitis B virus glycoprotein-derived peptides by MHC class I. Virology 384:12-5
Block, Timothy M; Guo, Haitao; Guo, Ju-Tao (2007) Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis 11:685-706, vii
Gu, Baohua; Mason, Peter; Wang, Lijuan et al. (2007) Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antivir Chem Chemother 18:49-59
Zhou, Tianlun; Guo, Haitao; Guo, Ju-Tao et al. (2006) Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res 72:116-24
Simsek, Ender; Lu, Xuanyong; Ouzounov, Serguey et al. (2006) alpha-Glucosidase inhibitors have a prolonged antiviral effect against hepatitis B virus through the sustained inhibition of the large and middle envelope glycoproteins. Antivir Chem Chemother 17:259-67
Simsek, Ender; Mehta, Anand; Zhou, Tianlun et al. (2005) Hepatitis B virus large and middle glycoproteins are degraded by a proteasome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme. J Virol 79:12914-20
Norton, Pamela A; Conyers, Bertha; Gong, Qiaoke et al. (2005) Assays for glucosidase inhibitors with potential antiviral activities: secreted alkaline phosphatase as a surrogate marker. J Virol Methods 124:167-72
Mehta, Anand S; Gu, Baohua; Conyers, Bertha et al. (2004) alpha-Galactosylceramide and novel synthetic glycolipids directly induce the innate host defense pathway and have direct activity against hepatitis B and C viruses. Antimicrob Agents Chemother 48:2085-90
Lu, Xuanyong; Tran, Trang; Simsek, Ender et al. (2003) The alkylated imino sugar, n-(n-Nonyl)-deoxygalactonojirimycin, reduces the amount of hepatitis B virus nucleocapsid in tissue culture. J Virol 77:11933-40